The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,753.00
Bid: 1,753.00
Ask: 1,754.00
Change: 19.50 (1.12%)
Spread: 1.00 (0.057%)
Open: 1,736.00
High: 1,753.50
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS: GlaxoSmithKline Gets Two Downgrades; Prudential Raised

Thu, 04th Feb 2021 09:27

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

----------

FTSE 100

----------

ODDO BHF CUTS GLAXOSMITHKLINE TO 'NEUTRAL' (OUTPERFORM) - PRICE TARGET 1,490 (1,770) PENCE

----------

DEUTSCHE BANK CUTS GLAXOSMITHKLINE TO 'SELL' (HOLD) - PRICE TARGET 1,150 (1,400) PENCE

----------

ODDO BHF RAISES RELX TO 'OUTPERFORM' (NEUTRAL)

----------

JEFFERIES RAISES PRUDENTIAL TO 'BUY' ('HOLD') - PRICE TARGET 1,450 (1,455) PENCE

----------

CREDIT SUISSE RAISES ADMIRAL GROUP TARGET TO 2,290 (1,870) PENCE - 'UNDERPERFORM'

----------

DEUTSCHE BANK RAISES ST JAMES'S PLACE TARGET TO 1,250 (1,160) PENCE - 'HOLD'

----------

CREDIT SUISSE RAISES ASHTEAD GROUP TARGET TO 4,100 (3,775) PENCE - 'OUTPERFORM'

----------

RBC RAISES GLENCORE PRICE TARGET TO 300 (280) PENCE - 'OUTPERFORM'

----------

RBC RAISES GLENCORE PRICE TARGET TO 300 (280) PENCE - 'OUTPERFORM'

----------

BARCLAYS RAISES VODAFONE PRICE TARGET TO 175 (170) PENCE - 'OVERWEIGHT'

----------

GOLDMAN SACHS CUTS RIGHTMOVE PRICE TARGET TO 712 (754) PENCE - 'BUY'

----------

UBS RAISES RIGHTMOVE PRICE TARGET TO 630 (620) PENCE - 'NEUTRAL'

----------

GOLDMAN SACHS CUTS AUTO TRADER GROUP PRICE TARGET TO 679 (688) PENCE - 'BUY'

----------

CREDIT SUISSE RAISES DCC PRICE TARGET TO 6,450 (6,300) PENCE - 'OUTPERFORM'

----------

FTSE 250

----------

UBS RAISES CLOSE BROTHERS PRICE TARGET TO 1400 (995) PENCE - 'NEUTRAL'

----------

UBS RAISES ROYAL MAIL TO 'BUY' ('NEUTRAL') - TARGET 445 (320) PENCE

----------

CREDIT SUISSE RAISES DIRECT LINE TARGET TO 405 (320.77) PENCE - 'OUTPERFORM'

----------

PEEL HUNT RAISES DOMINO'S PIZZA TO 'BUY' ('ADD') - TARGET 425 PENCE

----------

OTHER MAIN MARKET AND AIM

----------

JEFFERIES RAISES NCC GROUP PRICE TARGET TO 292 (245) PENCE - 'BUY'

----------

GOLDMAN RAISES ASOS PRICE TARGET TO 6,500 (5,800) PENCE - 'BUY'

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.